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Abstract
Aims Although hypertensive patients with low baseline HDL cholesterol levels have a higher incidence of diabetes
mellitus, whether changing levels of HDL over time are more strongly related to the risk of new diabetes in hypertensive
patients has not been examined.
Methods Incident diabetes mellitus was examined in relation to baseline and in-treatment HDL levels in 7485
hypertensive patients with no history of diabetes randomly assigned to losartan- or atenolol-based treatment.
Results During 4.7  1.2 years follow-up, 520 patients (6.9%) developed new diabetes. In univariate Cox analyses,
compared with the highest quartile of HDL levels (> 1.78 mmol/l), baseline and in-treatment HDL in the lowest quartile
(< 1.21 mmol/l) identified patients with > 5-fold and > 9 fold higher risks of new diabetes, respectively; patients with
baseline or in-treatment HDL in the 2nd and 3rd quartiles had intermediate risk of diabetes. In multivariable Cox
analyses, adjusting for randomized treatment, age, sex, race, prior anti-hypertensive therapy, baseline uric acid, serum
creatinine and glucose entered as standard covariates, and in-treatment non-HDL cholesterol, Cornell product left
ventricular hypertrophy, diastolic and systolic pressure, BMI, hydrochlorothiazide and statin use as time-varying
covariates, the lowest quartile of in-treatment HDL remained associated with a nearly 9-fold increased risk of new
diabetes (hazard ratio 8.7, 95% CI 5.0–15.2), whereas the risk of new diabetes was significantly attenuated for baseline
HDL < 1.21 mmol/l (hazard ratio 3.9, 95% CI 2.8–5.4).
Conclusions Lower in-treatment HDL is more strongly associated with increased risk of new diabetes than baseline
HDL level.
Diabet. Med. 30, 1189–1197 (2013)
Introduction
The high and increasing prevalence of hyperglycaemia and
Type 2 diabetes mellitus [1] and the associated greater risk of
cardiovascular disease [2,3] make a better understanding of
the risk factors for diabetes an important area of investiga-
tion. There is a well-established association between blood
pressure and insulin resistance [4–6], although this relation-
ship partially reflects parallel effects of obesity and age [4,5].
Moreover, hypertension and diabetes frequently coexist,
with the combination associated with a 2- to 3-fold increased
risk of cardiovascular disease [2,3,7]. These findings, taken
together with the increased long-term cardiovascular risk
associated with the development of new diabetes in hyper-
tensive patients [2], suggest that prevention of diabetes in
hypertensive patients may have prognostic benefit.
Low levels of HDL cholesterol have been implicated in the
development of insulin resistance and diabetes [8–16]. Low
HDL levels correlate significantly with increased insulin
resistance and fasting insulin levels [8,9] and low levels of
HDL at baseline measurement predict low insulin-sensitivity
index values and increased insulin resistance at subsequent
follow-up [9,10]. Low baseline HDL levels have also been
strongly linked to the development of diabetes in the general
population [11,12], Pima Indians [13,14], subjects with
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pre-diabetes [15] and in the current population of hyperten-
sive patients with electrocardiographic left ventricular hyper-
trophy [16].
However, HDL levels decrease with age and weight gain
[17] and often in response to increasing statin therapy. As a
consequence, it is unclear if a single, baseline measurement of
HDL will best stratify diabetes risk or whether changing
levels of HDL over time would more strongly reflect the risk
of diabetes. Therefore, the purpose of the present study was
to compare the predictive value of baseline and in-treatment
HDL levels for development of diabetes and to determine
whether HDL remained associated with a higher diabetes
risk after adjusting for the potential confounding effects of
risk factors, including hydrochlorothiazide [18] and statin
therapy [19], on diabetes incidence, and for the previously
demonstrated relations of randomized treatment allocation,
prior anti-hypertensive treatment and in-treatment electro-
cardiographic left ventricular hypertrophy to new diabetes in
the current study population [16,20].
Subjects and methods
Patient selection and treatment
The LIFE Study enrolled 9193 hypertensive patients with
electrocardiographic left ventricular hypertrophy by Cornell
voltage-duration product and/or Sokolow-Lyon voltage cri-
teria on a screening electrocardiographic in a prospective,
double-blind randomized study that compared cardiovascu-
lar morbidity and mortality with use of losartan-based
treatment as opposed to atenolol-based treatment, as previ-
ously described in detail [20,21]. The study was approved by
all ethics committees concerned and all participants gave
informed written consent. The 1195 patients with diabetes
mellitus at study baseline [16,20] and 513 additional patients
without diabetes who were missing baseline HDL levels were
excluded, leaving 7485 patients who were at risk of
developing diabetes in the present study. The 513 patients
with missing baseline HDL levels were similar to the 7485
patients included in the study with respect to age, gender,
randomized treatment allocation, baseline systolic pressure,
plasma glucose and severity of electrocardiographic left
ventricular hypertrophy by Cornell product criteria.
Blinded treatment was begun with losartan 50 mg or
atenolol 50 mg daily and matching placebo of the other
agent, with up-titration of study medication to 100 mg and
addition of hydrochlorothiazide and other anti-hypertensive
therapies to achieve a pressure of  140/90 mmHg as
previously reported [21].
Electrocardiography and lipid measurements
Study electrocardiogram were obtained at baseline, 6 months
and yearly follow-up until study termination or patient death
and were interpreted as previously reported [20,21]. Cornell
product> 2440 mm 9 msor Sokolow-Lyon voltage> 38 mm
were used to identify left ventricular hypertrophy [20,21].
Serum total cholesterol and HDL were measured in two
central laboratories as previously reported [22]. LDL cho-
lesterol and triglycerides were not measured. Non-HDL
cholesterol was calculated as total cholesterol minus HDL.
Treatment of lipids was at the discretion of study investiga-
tors, but all treatment was reported [22].
Endpoint determination
New-onset diabetes was a pre-specified secondary endpoint
in LIFE and was initially defined according to 1985 World
Health Organization criteria [16,23]. Because new recom-
mendations for the diagnosis of Type 2 diabetes were
published by the World Health Organization in 1999 while
the LIFE study was in progress [24], it was decided that all
patients who were diagnosed with new-onset diabetes would
be included in analyses regardless of whether the diagnosis
was based on 1985 or 1999 criteria [16,23,24].
Statistical analyses
Data management and analysis were performed with SPSS
version 12.0 software (SPSS Inc., Chicago, IL, USA). Data
are presented as mean  SD for continuous variables and
proportions for categorical variables. Differences in preva-
lences were compared using v2 analyses and of mean values
using the unpaired t-test.
The relation of new-onset diabetes to HDL was assessed
using Cox proportional hazards models with patients cate-
gorized into quartiles according to HDL levels at baseline;
the risk of new diabetes was calculated comparing each of
the first three quartiles of HDL against the highest quartile of
HDL. The predictive value of baseline HDL was determined
using baseline quartiles of HDL entered as standard covari-
ates in the Cox models; the predictive value of in-treatment
levels of HDL was determined using baseline and in-
treatment quartiles of HDL entered as time-varying covari-
ates. Independence of the relationship of new-onset diabetes
to baseline and in-treatment HDL was evaluated in multi-
variable Cox models that adjusted for randomized treatment
with losartan vs. atenolol, age, sex, race, prior anti-hyper-
tensive therapy, baseline uric acid, serum creatinine and
glucose entered as standard covariates and, for in-treatment
non-HDL cholesterol, Cornell product left ventricular hyper-
trophy, diastolic and systolic pressure, BMI, hydrochlorothi-
azide and statin use treated as time-varying covariates.
Baseline HDL was also included as a standard covariate in
the multivariable Cox analyses examining in-treatment
HDL. Analyses were also performed stratifying the popula-
tion by sex, age, prior anti-hypertensive treatment, random-
ized treatment allocation, treatment with a statin at any time
during the study, median baseline serum glucose and BMI,
median of the average systolic blood pressure during treat-
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ment and the median decrease in electrocardiographic left
ventricular hypertrophy by Cornell product and Sokolow-
Lyon voltage during the study, using in-treatment HDL
entered as a continuous variable for simplicity of these
analyses. For all tests, a two-tailed P-value < 0.05 was
required for statistical significance.
The relationship of incident diabetes over time to changing
quartiles of HDL during treatment was illustrated using a
modified Kaplan–Meier method [25] implemented in SAS
release 8.2 (SAS Institute, Cary, NC, USA) on the WIN_PRO
platform. Using this method, HDL quartile assignment is
updated each year and patients may be variably included in
one curve or another at different times during follow-up.
These modified Kaplan–Meier curves illustrate the results of
time-varying covariate analyses.
Results
During mean follow-up of 4.7  1.2 years, new-onset dia-
betes mellitus developed in 520 patients (6.9%). Demo-
graphic and clinical characteristics of patients according to
development of diabetes are compared in Table 1. As
previously reported [16], patients who developed diabetes
were more likely to have had prior anti-hypertensive treat-
ment, less likely to have been randomized to losartan-based
therapy, more obese, had higher serum glucose, creatinine
and uric acid levels, and lower total cholesterol levels.
Blood pressure and electrocardiographic left ventricular
hypertrophy measurements at baseline and changes in these
measurements between baseline and last in-study determina-
tion or last measurement prior to development of diabetes
are shown in Table 2. Patients who developed diabetes had
higher baseline systolic pressures, greater decreases in systolic
and diastolic pressure, more severe baseline left ventricular
hypertrophy by Cornell product and less severe baseline left
ventricular hypertrophy by Sokolow-Lyon voltage, but had
similar changes in diastolic pressure and both electrocardio-
graphic left ventricular hypertrophy criteria compared with
patients without diabetes.
HDL and non-HDL cholesterol levels at baseline and at
each year of treatment in relation to the development of
diabetes are shown in Table 3. Baseline and yearly in-
treatment HDL levels were significantly lower in patients
who developed diabetes. In contrast, non-HDL cholesterol
Table 1 Baseline demographic and clinical characteristics in relation to development of new diabetes mellitus
Variables No diabetes (n = 6965) New diabetes (n = 520) P-value
Age (years) 66.9  7.0 66.5  6.8 0.166
Sex (% female) 54.3 51.3 0.190
Race (% black) 5.0 5.6 0.559
Randomized to losartan (%) 50.9 42.3 < 0.001
History of ischaemic heart disease (%) 14.8 14.8 0.990
History of myocardial infarction (%) 5.8 6.2 0.730
History of heart failure (%) 1.5 1.9 0.389
History of stroke (%) 3.8 4.4 0.479
History of peripheral vascular disease (%) 5.4 6.2 0.464
Current smokers (%) 16.8 16.2 0.683
Prior anti-hypertensive treatment (%) 70.4 80.2 < 0.001
BMI (kg/m2) 27.5  4.5 30.5  5.2 < 0.001
Serum glucose (mmol/l) 5.41  0.95 6.50  1.60 < 0.001
Serum creatinine (lmol/l) 85.8  19.9 89.3  20.5 < 0.001
Total cholesterol (mmol/l) 6.09  1.11 5.91  1.16 < 0.001
Non-HDL cholesterol (mmol/l) 4.55  1.10 4.60  1.14 0.304
Uric acid (lmol/l) 328  78 359  73 < 0.001
Urine albumin:creatinine ratio (mg/mM) 5.8  28.1 7.0  20.4 0.359
Table 2 Baseline and change from baseline to last in-study
measurement of blood pressure and electrocardiographic left
ventricular hypertrophy in relation to development of new diabetes
mellitus
Variables
No diabetes
(n = 6965)
New diabetes
(n = 520) P-value
Baseline measurements
Systolic blood
pressure (mmHg)
174  14 177  14 < 0.001
Diastolic blood
pressure (mmHg)
98  9 99  9 0.090
Cornell voltage-
duration product
(mm 9 ms)
2805  1038 2980  1146 < 0.001
Sokolow-Lyon
voltage (mm)
30.3  10.4 29.1  10.2 0.015
Change from baseline to last measurement*
Systolic blood
pressure (mmHg)
–29  20 –32  19 0.010
Diastolic blood
pressure (mmHg)
–17  10 –19  10 < 0.001
Cornell voltage-
duration product
(mm 9 ms)
–210  849 –223  908 0.747
Sokolow-Lyon
voltage (mm)
–3.9  7.3 –4.4  7.3 0.147
*Change from baseline to last in-study measurement or last
measurement prior to diagnosis of new diabetes.
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levels at baseline and at each of the first 4 years of the study
did not differ between patients who did and did not develop
diabetes, but were significantly lower at year 5 in patients
who developed diabetes.
Because both hydrochlorothiazide and statin therapy have
been implicated in the development of diabetes [18,19], the
relationship of baseline and in-treatment hydrochlorothia-
zide and statin use to development of diabetes are examined
in Table 4. By protocol design [23], use of hydrochlorothi-
azide was uncommon at baseline and increased substantially
by year 1. Hydrochlorothiazide therapy at baseline was
similar in patients with and without new-onset diabetes, but
became significantly more common at each in-treatment year
in patients who developed diabetes. Statin therapy was
relatively uncommon and similar in patients with and
without new diabetes at baseline and year 1 of the study,
but was significantly more common in patients with new
diabetes from year 2 to year 5 of the study.
The relationship of new-onset diabetes to quartiles of HDL
cholesterol levels at baseline and during treatment is shown in
Table 5 andFig. 1. In univariateCox analyses, comparedwith
the highest quartile of HDL levels (HDL > 1.78 mmol/l),
baseline and in-treatment HDL in the lowest quartile
(< 1.21 mmol/l) identified patients with > 5-fold and > 9-fold
higher risk of newdiabetes, respectively; patientswith baseline
or in-treatment HDL in the 2nd and 3rd quartiles had
intermediate increased risk of diabetes. In multivariable Cox
analyses, the lowest quartile of in-treatment HDL remained
associated with a nearly 9-fold increased risk of new diabetes,
whereas the adjusted risk of new diabetes associated with a
baseline HDL < 1.21 mmol/l was significantly attenuated.
The full multivariable Cox model for prediction of new
diabetes by quartiles of in-treatmentHDL is shown inTable 6.
Of note in a parallel multivariable Coxmodel adjusting for the
same variables, lower in-treatment HDL treated as a contin-
uous variable remained strongly associated with new-onset
diabetes, with each 1 SD of the baseline mean lower in-
treatment HDL (0.44 mmol/l) associated with a greater than
3-fold higher adjusted risk of new diabetes (hazard ratio 3.46,
95% CI 2.79–4.26, P < 0.001). The association between
lower serum HDL and an increased risk of new diabetes was
statistically similar in all subsets of the population (Table 7).
Discussion
These findings demonstrate that lower in-treatment levels of
HDL during anti-hypertensive therapy are more strongly
associated with increased risk of new-onset diabetes than
baseline HDL levels. The greater predictive value of low in-
treatment HDL persists and is not attenuated in multivari-
able models that adjust for other known and potential risk
factors for diabetes, the possible impact of concurrent
treatment with hydrochlorothiazide and statins [18,19],
and the previously demonstrated impacts of losartan vs.
atenolol treatment, previous anti-hypertensive therapy and
in-treatment electrocardiographic left ventricular hypertro-
phy on diabetes risk is this population [16,20]. These findings
support the value of serial measurement of HDL to better
estimate diabetes risk in hypertensive patients.
Low HDL levels have been related to insulin resistance and
to increased fasting insulin levels [8,9]. More importantly,
Table 3 Baseline and in-treatment HDL and non-HDL cholesterol
levels in relation to development of new diabetes mellitus
Variables
No diabetes
(n = 6965)
New diabetes
(n = 520) P-value
HDL cholesterol (mmol/l)*
Baseline 1.54  0.44 1.30  0.37 < 0.001
Year 1 1.38  0.40 1.18  0.32 < 0.001
Year 2 1.37  0.37 1.18  0.32 < 0.001
Year 3 1.43  0.36 1.23  0.30 < 0.001
Year 4 1.47  0.37 1.26  0.33 < 0.001
Year 5 1.49  0.37 1.27  0.30 < 0.001
Non-HDL cholesterol (mmol/l)†
Baseline 4.55  1.10 4.60  1.14 0.304
Year 1 4.68  1.12 4.70  1.12 0.671
Year 2 4.70  1.10 4.71  1.12 0.783
Year 3 4.51  1.05 4.44  1.08 0.181
Year 4 4.34  1.01 4.29  1.04 0.321
Year 5 4.33  1.04 4.12  1.00 < 0.001
*P < 0.001 for no diabetes vs. new diabetes by repeated-
measures ANOVA.
†P = 0.353 for no diabetes vs. new diabetes by repeated-
measures ANOVA.
Table 4 Baseline and in-treatment hydrochlorothiazide and statin use
in relation to development of new diabetes mellitus
Variables
No diabetes
(n = 6965)
New diabetes
(n = 520) P-value
Hydrochlorothiazide use
Baseline
(%)
0.9 1.0 0.825
Year 1
(%)
67.0 78.1 < 0.001
Year 2
(%)
66.8 78.1 < 0.001
Year 3
(%)
66.3 76.0 < 0.001
Year 4
(%)
65.7 73.5 < 0.001
Year 5
(%)
52.7 58.1 0.021
Statin use
Baseline
(%)
7.1 8.8 0.157
Year 1
(%)
5.7 7.5 0.101
Year-2
(%)
22.2 31.9 < 0.001
Year 3
(%)
21.4 31.5 < 0.001
Year 4
(%)
20.5 31.2 < 0.001
Year 5
(%)
19.6 30.0 < 0.001
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low HDL levels at baseline measurement predict low insulin-
sensitivity index values 13 years later [9], increased insulin
resistance at 8-year follow-up [10] and subsequent develop-
ment of diabetes [11–16]. In the Framingham Offspring
study [11,12], low baseline HDL was associated with a
nearly 2.2-fold higher risk of diabetes after adjustment for
age, sex, BMI, fasting glucose and triglyceride levels, waist
circumference and a measure of insulin resistance at baseline.
Lower baseline HDL was also associated with an increased
risk of new diabetes in population-based studies of Pima
Indians [13,14] and in 830 pre-diabetic subjects enrolled in
the Insulin Resistance Atherosclerosis Study (IRAS) [15].
Finally, in an earlier analysis of findings from the LIFE study,
in which only baseline predictor variables were included
[16], each mmol/l decrease in baseline HDL was associated
with a nearly 2.8-fold increased risk of new diabetes after
adjusting for randomized and prior anti-hypertensive treat-
ment, baseline glucose, BMI and systolic pressure.
The current study extends these previous findings to a large
population of hypertensive patients, demonstrating that HDL
at baseline is a strong predictor of new-onset diabetes after
adjusting for numerous other possible diabetes risk factors.
More importantly, the current study demonstrates that in-
treatment HDL, treated as a time-varying covariate in Cox
analyses, has substantially better predictive power than
baselineHDL for the development of newdiabetes. Persistence
or development of anHDL < 1.21 mmol/l (the lowest quartile
at LIFE study baseline) during treatmentwas associated with a
nearly 9-fold increased adjusted risk of new diabetes develop-
ing during nearly 5 years’ mean follow-up, compared with a
3.9-fold higher risk associatedwith baseline values in the same
quartile after similarmultivariable adjustment.Moreover, low
Table 5 Univariate and multivariable Cox regression analyses to assess the relation of new-onset diabetes mellitus to quartiles of baseline and in-
treatment HDL cholesterol levels
Analysis
Hazard ratios (95% CI)
Quartile 1
HDL < 1.22
Quartile 2
HDL 1.22–1.47
Quartile 3
HDL 1.48–1.78
Quartile 4
HDL > 1.78
Univariate Cox model
Baseline HDL 5.1 (3.8–6.9) 2.8 (2.0–3.8) 2.1 (1.5–2.9) 1
In-treatment HDL 9.1 (5.9–13.8) 3.7 (2.4–5.8) 2.0 (1.3–3.3) 1
Multivariate Cox model*
Baseline HDL 3.9 (2.8–5.4) 2.4 (1.7–3.4) 1.9 (1.3–2.7) 1
In-treatment HDL† 8.7 (5.0–15.2) 3.6 (2.2–6.1) 2.0 (1.2–3.4) 1
*Adjusted for randomized treatment with losartan vs. atenolol, age, sex, race, prior anti-hypertensive therapy, baseline uric acid, serum
creatinine and glucose entered as standard covariates, and for in-treatment non-HDL cholesterol, Cornell product left ventricular
hypertrophy, diastolic and systolic pressure, BMI, hydrochlorothiazide and statin use treated as time-varying covariates.
†Also adjusted for baseline HDL cholesterol level.
Table 6 Full multivariable Cox regression model relating new-onset diabetes mellitus to quartiles of in-treatment HDL cholesterol levels and other
predictor variables*
Variables Hazard ratio 95% CI P-value
In-treatment HDL cholesterol quartile
Quartile 1 (< 1.22 mmol/l) 8.7 5.0–15.2 < 0.001
Quartile 2 (1.22–1.47 mmol/l) 3.6 2.2–6.1 < 0.001
Quartile 3 (1.48–1.78 mmol/l) 2.0 1.2–3.4 0.005
Quartile 4 (> 1.78 mmol/l) 1 (reference group) — —
Age (per 7.0 years) 1.11 1.01–1.22 0.040
Sex (female) 1.65 1.33–2.04 < 0.001
Race (black) 0.93 0.62–1.40 0.739
Prior anti-hypertensive treatment 1.24 0.99–1.54 0.060
Randomized treatment with losartan 0.77 0.64–0.91 0.003
Baseline HDL cholesterol (per 0.44 mmol/l) 1.18 0.82–1.71 0.381
Baseline serum glucose (per 1.05 mmol/l) 1.70 1.61–1.78 < 0.001
Baseline serum creatinine (per 19.9 lmol/l) 0.96 0.85–1.06 0.388
Baseline uric acid (per 78 lmol/l) 1.26 1.17–1.37 < 0.001
In-treatment non-HDL cholesterol (per 1.10 mmol/l) 0.65 0.59–0.71 < 0.001
In-treatment BMI (per 4.6 kg/m2) 1.40 1.30–1.51 < 0.001
In-treatment systolic blood pressure (per 14 mmHg) 1.27 1.17–1.36 < 0.001
In-treatment diastolic blood pressure (per 9 mmHg) 1.39 1.26–1.52 < 0.001
In-treatment Cornell product left ventricular hypertrophy 1.07 0.89–1.28 0.475
In-treatment statin use 1.04 0.74–1.29 0.708
In-treatment hydrochlorothiazide use 1.36 1.12–1.66 0.002
*Hazard ratios for continuous variables calculated for 1 SD of the baseline mean value.
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in-treatment HDL remained associated with a markedly
increased diabetes risk when HDL was considered as a
continuous variable. Importantly, the predictive value of low
in-treatment HDL persisted after adjusting for the previously
demonstrated decreased risk associatedwith randomization to
losartan and increased risks associated with prior anti-hyper-
Table 7 Multivariable Cox analyses to assess the predictive value of in-treatment HDL for new-onset diabetes in relevant subgroups of the study
population
Subgroup
New
diabetes (n)
Hazard
ratio* 95% CI
P-value for
interaction
Sex
Female (n = 4050) 267 3.27 2.35–4.55 0.354
Male (n = 3435) 253 4.22 3.18–5.59
Age
< 65 years (n = 2881) 204 3.51 2.51–4.90 0.145
 65 years (n = 4604) 316 3.98 3.01–5.26
Prior anti-hypertensive treatment
No (n = 2167) 103 2.79 1.74–4.49 0.459
Yes (n = 4901) 417 4.08 3.20–5.16
Randomized treatment
Atenolol (n = 3721) 300 2.98 2.23–3.99 0.062
Losartan (n = 3764) 220 4.99 3.64–6.76
Treatment with a statin at any time during study
No (n = 5740) 351 3.51 2.71–4.55 0.417
Yes (n = 1745) 169 4.31 2.93–6.35
Median baseline serum glucose
 5.30 mmol/l (n = 3802) 91 3.70 2.29–6.01 0.442
> 5.30 mmol/l (n = 3683) 429 3.26 2.58–4.12
Median baseline BMI
 27.14 kg/m2 (n = 3727) 135 2.92 1.97–4.32 0.898
> 27.14 kg/m2 (n = 3758) 385 4.09 3.16–5.26
Median of the average systolic blood pressure during treatment
< 147 mmHg (n = 3825) 250 3.65 2.67–4.98 0.983
 147 mmHg (n = 3660) 270 3.95 2.94–5.36
Median decrease in Cornell product left ventricular hypertrophy during treatment
 223 mm 9 ms
(n = 3665)
251 3.71 2.71–5.07 0.948
> 223 mm 9 ms (n = 3820) 269 3.74 2.79–5.07
Median decrease in Sokolow-Lyon voltage left ventricular hypertrophy during treatment
 3.5 mm (n = 3840) 252 4.30 3.14–5.86 0.810
> 3.5 mm (n = 3645) 268 3.34 2.50–4.49
*Hazard ratio for each 1 SD of mean of baseline HDL (0.44 mmol/l) with lower HDL entered as a continuous variable adjusted for the same
covariates as in Table 5.
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tensive treatment [16], the slightly increased risk reported for
statin therapy [19], the potential risk associated with changing
levels of BMI and use of hydrochlorothiazide [18] during the
study, baseline serum glucose levels and other potential risk
factors, and the previously demonstrated decreased risk of
diabetes associated with in-treatment resolution or absence of
electrocardiographic left ventricular hypertrophy by Cornell
product criteria [20].
The predictive value of in-treatment HDL for new-onset
diabetes was similar in all subgroups examined (Table 7).
Particularly of note, lower in-treatment HDL had statistically
similar predictive value in groups defined by prior anti-
hypertensive treatment, randomized treatment allocation to
either losartan or atenolol, and by median baseline values of
BMI and serum glucose, despite the markedly different
incidence of diabetes in these subgroups. In addition, there
was no significant interaction of in-treatment HDL with
statin use in this study, suggesting that neither the potential
impact of statins on HDL levels nor the possible relationship
of incidence diabetes to statin use [19] significantly contrib-
utes to the impact of low HDL on diabetes risk.
Cell-based and clinical studies suggest a number of
possible mechanisms via which HDL may play a role in
plasma glucose control and development of diabetes. In
isolated human and rat pancreatic b-cells [26], HDL
appeared to counter the negative effects of oxidized LDL
on insulin secretion. Moreover, incubation of cultured
murine pancreatic b-cells with HDL significantly increased
acute-phase, glucose-stimulated insulin and reversed the
blunting of this effect by oxidized LDL [27], with the
absence of any changes in insulin gene or protein expression,
suggesting that HDL may be directly stimulating insulin
secretion. Among 13 patients with Type 2 diabetes, a 4-h
infusion of reconstituted HDL produced a greater fall in
plasma glucose and greater increases in plasma insulin and
the homeostasis model assessment of b-cell function index
than matching placebo [27]. In addition, acetyl-CoA car-
boxylase b phosphorylation in skeletal muscle biopsies was
increased by 70% after reconstituted HDL infusion and
HDL increased glucose uptake by 177% in primary human
skeletal muscle cell cultures established from patients with
Type 2 diabetes, suggesting activation of the AMP-mediated
protein kinase pathway [27]. These experiments in patients
with Type 2 diabetes provide a putative framework for how
low HDL could promote the development of diabetes via
worsening glycaemic control by decreasing plasma insulin
and attenuating skeletal muscle glucose uptake and suggest
that low HDL cholesterol in patients who develop diabetes
may be a marker of hepatic insulin resistance.
Study limitations
Several limitations of our study warrant review. First,
inclusion criteria of hypertension and electrocardiographic
left ventricular hypertrophy by either Cornell product or
Sokolow-Lyon voltage increased the risk of new-onset
diabetes in the population; as a consequence, our findings
may not be representative of other lower-risk populations.
Second, the absence of triglyceride measurements in the LIFE
study does not allow determination whether in-treatment
HDL levels would remain predictive of diabetes after
adjusting for the demonstrated predictive value of baseline
and changes in triglyceride levels over time [28]. Third, the
absence of fasting insulin levels or more sophisticated
measures of insulin resistance makes it impossible to deter-
mine from the current analyses whether the association of
low HDL levels with incident diabetes is a direct one or
rather a reflection of the association of low HDL with
increased hepatic insulin resistance [26,27].
Implications
First, these findings suggest that tracking HDL levels over
time may provide important insights into the risk of
developing diabetes. Second, these findings raise the possi-
bility that therapies aimed at raising HDL levels could reduce
the risk of diabetes in high-risk populations with low HDLs.
This possibility is supported by the recent post hoc analysis
of the Investigation of Lipid Level Management to Under-
stand its Impact in Atherosclerotic Events (ILLUMINATE)
trial, which compared the effect of the combination of
torcetrapib, a cholesteryl ester transfer protein inhibitor, and
atorvastatin with atorvastatin alone on glycaemic control in
a subset of 6661 patients with diabetes [29]. Patients on the
combination of torecetrapib and atorvastatin had signifi-
cantly lower 3-month plasma glucose levels and insulin
levels, lower insulin resistance and lower 6-month HbA1c
levels [29]. Although ILLUMINATE was terminated early
because of an excess of deaths and cardiovascular events in
the torcetrapib arm of the study [30], there is increasing
evidence that this increase in harm may have been attribut-
able to off-target effects of torcetrapib that produce an
increase in blood pressure, serum sodium and bicarbonate,
and a decrease in serum potassium [30]. However, as noted
above, the association of low HDL levels with incident
diabetes could also be explained by increased insulin resis-
tance. As a consequence, additional studies which examine
direct markers of insulin resistance, and further study of both
the safety and efficacy of other cholesteryl ester transfer
protein inhibitors that do not appear to share these off-target
effects will be required in order to assess whether treatment
to increase HDL levels may be of clinical value in preventing
the development of diabetes or whether low HDL levels are
solely a marker of increased insulin resistance.
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